In a report released yesterday, Joel Beatty from Robert W. Baird maintained a Buy rating on Editas Medicine (EDIT – Research Report), with a price target of $30.00. The company’s shares closed last Thursday at $19.15, close to its 52-week low of $9.59.
According to TipRanks.com, Beatty is a 3-star analyst with an average return of 2.0% and a 47.8% success rate. Beatty covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.
The word on The Street in general, suggests a Hold analyst consensus rating for Editas Medicine with a $21.00 average price target, which is a 13.3% upside from current levels. In a report issued on August 3, Chardan Capital also reiterated a Buy rating on the stock with a $60.00 price target.
The company has a one-year high of $73.03 and a one-year low of $9.59. Currently, Editas Medicine has an average volume of 1.78M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.
Read More on EDIT:
- Werner Enterprises (WERN) Gets a Buy Rating from Robert W. Baird
- Robert W. Baird Maintains Their Buy Rating on Hub Group (HUBG)
- Cognex (CGNX) Gets a Hold Rating from Robert W. Baird
- Mizuho Securities Maintains a Buy Rating on Provident Financial Services (PFS)
- Robert W. Baird Sticks to Their Hold Rating for Intellia Therapeutics (NTLA)